To our knowledge, this is the first comprehensive and critical summary of the top evidence for CDK4/6 inhibitors in combination with ET for breast cancer as a way to provide more rational and effective evidence-based medical evidence for clinical decision-making. The gene discussed is CDK4; the disease is breast cancer.